RG-7410
TAAR1 agonist
From Wikipedia, the free encyclopedia
RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed.[1][2] Its route of administration was unspecified.[1]
Other namesRG7410
Routes of
administrationUnspecified[1]
administrationUnspecified[1]
| Clinical data | |
|---|---|
| Other names | RG7410 |
| Routes of administration | Unspecified[1] |
| Drug class | Trace amine-associated receptor 1 (TAAR1) agonist[1] |
| Identifiers | |
| CAS Number | |
The drug reached phase 1 clinical trials prior to the discontinuation of its development.[1][2] It was under development by Hoffmann-La Roche.[1][2] RG-7410 was first disclosed by January 2014[3] and a phase 1 trial was reported to have been completed by October 2014.[4]
See also
- Ralmitaront (RG-7906; RO-6889450)
- RG-7351
- Ulotaront (SEP-363856; SEP-856)